Table 1.
Hypermethylation in genes associated with risk factors in patients with head and neck squamous cell carcinoma in the 85 identified studies.
| Author | Impact factor | Type of Study | Population | Sample size | Anatomic location | Epigenetic alteration | Assay |
|---|---|---|---|---|---|---|---|
| Cordeiro-Silva et al. | 1.698 | Case–Control | Brazil | 70/41 | OC | CDKN2A, SFN, EDNRB, RUNX3 | MSP |
| Sanchez-Cespedes et al. | 9.329 | Retrospective | USA | 95 | HNC | CDKN2A, MGMT, GSTP1, DAPK | MSP |
| Markowski et al. | 1.554 | Retrospective | Poland | 21 | larynx | HIC1 | qRT-PCR |
| Virani et al. | 3.362 | Retrospective | USA | 346 | HNC | CCNA1, NDN, CD1A, DCC, CDKN2A, GADD45A | MSP |
| Shintani et al. | 1.521 | Retrospective | Japan | 17 | OC | CDKN2A | MSP |
| Agnese et al. | 9.269 | Retrospective | Italy | 173 | HNC | CDKN2A | MSP |
| Kawakami et al. | 2.915 | Retrospective | Japan | 104 | OP | CDKN2A | MSP |
| Ruesga et al. | 5.992 | Prospective | Spain | 175 | OC | CDKN2A | MSP |
| Zheng et al. | 4.125 | Case–Control | USA | 208/ 245 | HNC | CDKN2A | qRT-PCR |
| Sun et al. | 3.234 | Prospective | USA | 197 | OC and OP | CDKN2A, CCNA1, DCC, TIMP3, MGMT, DAPK, MINT31 | MSP |
| Calmon et al. | 2.805 | Prospective | Brazil | 43 | HNC | CDKN2A, DAPK1, CDH1, ADAM23 | MSP |
| Langevin et al. | 5.108 | Case–Control | USA | 92/ 92 | HNC | FGDA, SERPINF1, WDR39, IL27, HYAL2, PLEKHA6 | qRT-PCR |
| Zhang et al. | 3.234 | Retrospective | Japan | 10 | OP | LCR | MSP |
| Hasegawa et al. | 5.979 | Retrospective | Israel | 80 | HNC | CDKN2A, DAPK, CDH1, RASSF1A | MSP |
| Misawa et al. | 3.081 | Retrospective | Japan | 100 | HNC | CDKN2A | MSP |
| Marsit et al. | 5.649 | Retrospective | USA | 340 | HNC | CDH1 | MSP |
| Dikshit et al. | 5.649 | Retrospective | Italy | 235 | HNC | MGMT, DAPK, CDKN2A, CDH1 | MSP |
| Farias et al. | 3.025 | Retrospective | Brazil | 75 | HNC | CDKN2A | MSP |
| Wong et al. | 5.417 | Prospective | China | 73 | HNC | P15, CDKN2A | MSP |
| Smith et al. | 5.531 | Retrospective | USA | 137 | HNC | CCNA1, MGMT, DCC, CDKN2A | MSP |
| Shaw et al. | 3.93 | Retrospective | UK | 48 | OC | CDKN2A, CYGB, CDH1, TMEFF2 | MSP |
| Wong et al. | 0.795 | Retrospective | Taiwan | 64 | OC | DAPK, MGMT | MSP |
| Dong et al. | 1.859 | Prospective | China | 30 | OC | CDKN2A | MSP |
| Prez-Sayans et al. | 1.553 | Retrospective | Spain | 68 | OC | CDKN2A | MSP |
| Tran et al. | 1.859 | Prospective | Vietnam | 36 | OC | CDKN2A, RASSF1A | MSP |
| Kaur et al. | 5.531 | Prospective | India | 92 | OC | DCC, EDNRB, CDKN2A, KIF1A | MSP |
| Virani et al. | 3.135 | Retrospective | USA | 98 | HNC | CCNA1, NDN | MSP |
| Nakagawa et al. | 3.523 | Prospective | Japan | 58 | OC | LRP1B | qRT-PCR |
| Morandi et al. | 1.252 | Retrospective | Italy | 48 | OC | GP1BB, ZAP70, KIF1A, CDKN2A, CDH1, miR137, miR375 | MSP |
| Taioli et al. | 3.362 | Retrospective | USA | 88 | OC and OP | MGMT, CDKN2A, RASSF1 | MSP |
| Parfenov et al. | 9.423 | Prospective | USA | 129 | HNC | BARX2, IRX4, SIM2 | qRT-PCR |
| Lee et al. | 7.429 | Retrospective | Taiwan | 40 | OC | BEX1, LDOC1 | MSP |
| Chang et al. | 5.649 | Prospective | China | 90 | HNC | P15 | MSP |
| Schussel et al. | 1.186 | Prospective | Brazil | 47 | OC | DACT1, DACT2 | MSP |
| Wilson et al. | 5.108 | Prospective | USA | 6 | HNC | CDH1 | MSP |
| Nayak et al. | 2.272 | Retrospective | USA | 124 | HNC | TIMP3, DAPK | MSP |
| Ogi et al. | 8.738 | Retrospective | Japan | 96 | OC | CDKN2A, P15, P14, DCC, DAPK, MINT1, MINT2, MINT27, MINT31 | qRT-PCR |
| Colacino et al. | 3.234 | Retrospective | USA | 68 | HNC | GRB7, CDH11, RUNX1T1, SYBL1, TUSC3, SPDEF, RASSF1, STAT5A, MGMT, ESR2, JAK3, HSD17B12 | MSP |
| Langevin et al. | 4.327 | Retrospective | USA | 154 | HNC | DKK1, ZCCHC14, MARCH4, ANKRD33B, SLC6A5, INPP5A, ATAD3C, PWWP2B, SAFB2, GABRA1, KCNQ1, PTHLH, ARHGEF2, CIT, SH3BP5 | qRT-PCR |
| Misawa et al. | 8.738 | Prospective | Japan | 100 | HNC | GALR1 | MSP |
| Langevin et al. | 3.607 | Retrospective | USA | 82 | OC | GABBR1 | qRT-PCR |
| Bebek et al. | 5.985 | Prospective | USA | 42 | HNC | MDR1, IL8, RARB, TGFBR2 | MSP |
| Ohta et al. | 1.262 | Prospective | Japan | 44 | OC | CDKN2A, P14ARF | MSP |
| Furniss et al. | 4.125 | Retrospective | USA | 303 | HNC | LRE1 | MSP |
| Zhao et al. | 2.301 | Retrospective | China | 41 | nasopharynx | GALC | qRT-PCR |
| Hsiung et al. | 4.125 | Case–Control | USA | 278/ 526 | OC and OP | MTHFR | MSP |
| Sinha et al. | 3.135 | Prospective | India | 38 | OC | CDKN2A | MSP |
| Khor et al. | 2.244 | Prospective | Malaysia | 20 | OC | CDKN2A, DDAH2, DUSP1 | MSP |
| O'Regan et al. | 2.769 | Prospective | Ireland | 24 | OC and OP | CDKN2A | MSP |
| Weiss et al. | 4.722 | Retrospective | Germany | 86 | HNC | TIMP3, CDH1, CDKN2A, DAPK1,TCF21, CD44, MLH1, MGMT, RASSF1, CCNA1, LARS2, CEBPA | MSP |
| Sun et al. | 8.738 | Retrospective | USA | 197 | HNC | CCNA1, MGMT, MINT31 | MSP |
| Supic et al. | 4.602 | Prospective | Serbia | 96 | OC | CDKN2A, RASSF1A, DAPK, CDH1, MGMT, hMLH1, WIF1, RUNX3 | MSP |
| Weiss et al. | 3.562 | Prospective | Germany | 74/ 41 | HNC | TCF21 | MSP |
| Ai et al. | 5.485 | Retrospective | USA | 100 | HNC | CDKN2A | MSP |
| El-Naggar et al. | 6.501 | Retrospective | USA | 46 | HNC | CDKN2A | MSP |
| González-Ramírez et al. | 3.607 | Case–Control | Mexico | 50/200 | OC | MLH1 | MSP |
| Gemenetzidis et al. | 3.234 | Prospective | UK | 75 | HNC | FOXM1 | qRT-PCR |
| Ishida et al. | 3.607 | Prospective | Japan | 49 | OC | CDKN2A, P14, RB1, P21, P27, PTEN, P73, MGMT, GSTP | MSP |
| Righini et al. | 8.738 | Prospective | France | 90 | HNC | TIMP3, CDH1, CDKN2A,MGMT, DAPK, RASSF1 | MSP |
| Subbalekha et al. | 3.607 | Case–Control | Thailand | 69/37 | OC | LINE1 | MSP |
| Dong et al. | 8.738 | Prospective | USA | 46 | OP | RASSF1A | MSP |
| Ovchinnikov et al. | 2.884 | Case–Control | Australia | 143/31 | HNC | RASSF1A, DAPK1, CDKN2A | MSP |
| Demokan et al. | 2.760 | Prospective | Turkey | 77 | HNC | CDKN2A | MSP |
| Kresty et al. | 9.329 | Retrospective | USA | 26 | OC | CDKN2A, P14 | MSP |
| Marsit et al. | 5.334 | Prospective | USA | 68 | HNC | HGF, FGF, ATP10A, NTRK3, ZAP70, GP1BB, SRC, EGF, EPHA2 | MSP |
| Mielcarek-Kuchta et al. | 2.926 | Prospective | Poland | 53 | OC and OP | CDKN2A, CDH1, ATM, FHIT, RAR | MSP |
| Steinmann et al. | 2.301 | Prospective | Germany | 54 | HNC | RASSF1A, CDKN2A, MGMT, DAPK, RARß, MLH1, CDH1, GSTP1, RASSF2, RASSF4, RASSF5, MST1, MST2, LATS1, LATS2 | MSP |
| Tan et al. | 5.569 | Prospective | France | 42 | HNC | CDKN2A, CCNA1, DCC | MSP |
| Pannone et al. | 1.718 | Prospective | Italy | 64 | OC and OP | CDKN2A | MSP |
| Kulkarni et al. | 3.607 | Prospective | India | 60 | OC | CDKN2A, DAPK, MGMT | MSP |
| Huang et al. | 2.207 | Case–Control | Taiwan | 31/40 | OC | SOX1, PAX1, ZNF582 | MSP |
| Misawa et al. | 1.736 | Prospective | Japan | 46 | HNC | COL1A2 | MSP |
| Koscielny et al. | 0.492 | Prospective | Germany | 67 | HNC | CDKN2A | MSP |
| Miracca et al. | 5.569 | Prospective | Brazil | 47 | HNC | CDKN2A | MSP |
| Rosas et al. | 9.329 | Retrospective | USA | 30 | HNC | CDKN2A, DAPK, MGMT | MSP |
| Roh et al. | 8.738 | Prospective | USA | 353 | HNC | CDKN2A, DCC, EDNRB, KIF1A | MSP |
| Supic et al. | 2.495 | Retrospective | Serbia | 76 | OC | RUNX3, W1F1 | MSP |
| Sharma et al. | 2.495 | Prospective | India | 73 | HNC | CYP1A1, CYP2A13, GSTM1 | MSP |
| Choudhury et al. | 3.234 | Retrospective | India | 116 | HNC | CDKN2A, DAPK, RASSF1, BRAC1, GSTP1, CDH1, MLH1, MINT1, MINT2, MINT31 | MSP |
| Park et al. | 4.444 | Prospective | USA | 22 | OP | LCR | MSP |
| Balderas-Loaeza et al. | 5.531 | Prospective | Mexico | 62 | OC | LCR | MSP |
| Marsit et al. | 5.531 | Retrospective | USA | 350 | HNC | SFRP1, SFRP2, SFRP4, SFRP5 | MSP |
| Ayadi et al. | 1.826 | Retrospective | Tunisia | 44 | nasopharynx | CDKN2A, DLEC1, BLU, CDH1 | MSP |
| Puri et al. | 0.933 | Retrospective | USA | 51 | HNC | MLH1, MGMT, CDKN2A | MSP |
| Gubanova et al. | 8.738 | Prospective | USA | 40 | OP | SMG1 | qRT-PCR |
MSP: methylation specific PCR; OC: oral cancer; OP: oropharyngeal cancer; HNC: head and neck cancer.